During the 29-day observation period, the combined CPX-351/M3814 treatment showed no significant body weight changes (Fig. 7C) or reduction in hemoglobin and platelets levels (Fig. 7D), suggesting that addition of DNA-PK inhibitor to the optimized chemotherapy formulation CPX-351 provides a superior anti-leukemia effect while sparing normal hematopoietic cells. Here, PRKDC is linked to leukemia.